PerSurge (NOA-30) phase II trial of perampanel treatment around surgery in patients with progressive glioblastoma.
Saved in:
| Title: | PerSurge (NOA-30) phase II trial of perampanel treatment around surgery in patients with progressive glioblastoma. |
|---|---|
| Authors: | Heuer S; Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, INF 400, 69120, Heidelberg, Germany.; Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany., Burghaus I; Coordination Centre for Clinical Trials (KKS) Heidelberg, 69120, Heidelberg, Germany., Gose M; Coordination Centre for Clinical Trials (KKS) Heidelberg, 69120, Heidelberg, Germany., Kessler T; Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, INF 400, 69120, Heidelberg, Germany.; Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany., Sahm F; Department of Neuropathology, University Hospital Heidelberg, INF 224, 69120, Heidelberg, Germany.; CCU Neuropathology, German Consortium for Translational Cancer Research (DKTK), Geman Cancer Research Center (DKFZ), Heidelberg, Germany., Vollmuth P; Department of Neuroradiology, University Hospital Heidelberg, INF 400, 69120, Heidelberg, Germany., Venkataramani V; Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, INF 400, 69120, Heidelberg, Germany.; Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.; Department of Functional Neuroanatomy, Institute for Anatomy and Cell Biology, Heidelberg University, Heidelberg, Germany., Hoffmann D; Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, INF 400, 69120, Heidelberg, Germany.; Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany., Schlesner M; German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.; Biomedical Informatics, Data Mining and Data Analytics, University of Augsburg, Augsburg, Germany., Ratliff M; Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.; Neurosurgery Clinic, University Hospital Mannheim, 68167, Mannheim, Germany., Hopf C; Center for Mass Spectrometry and Optical Spectroscopy (CeMOS), Mannheim University of Applied Sciences, Paul-Wittsack Str. 10, 68163, Mannheim, Germany.; Medical Faculty, Heidelberg University, Heidelberg, Germany.; Mannheim Center for Translational Neuroscience (MCTN), Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany., Herrlinger U; Division of Clinical Neurooncology, Department of Neurology and Centre of Integrated Oncology, University Hospital Bonn, Bonn, Germany., Ricklefs F; Department of Neurosurgery, University Hospital Eppendorf, Martinistr. 52, 20246, Hamburg, Germany., Bendszus M; Department of Neuroradiology, University Hospital Heidelberg, INF 400, 69120, Heidelberg, Germany., Krieg SM; Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany., Wick A; Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, INF 400, 69120, Heidelberg, Germany., Wick W; Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, INF 400, 69120, Heidelberg, Germany.; Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany., Winkler F; Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, INF 400, 69120, Heidelberg, Germany. Frank.Winkler@med.uni-heidelberg.de.; Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany. Frank.Winkler@med.uni-heidelberg.de. |
| Source: | BMC cancer [BMC Cancer] 2024 Jan 26; Vol. 24 (1), pp. 135. Date of Electronic Publication: 2024 Jan 26. |
| Publication Type: | Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase II; Journal Article; Equivalence Trial |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1471-2407 |
|---|---|
| DOI: | 10.1186/s12885-024-11846-1 |
